# EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

> **NCT00041028** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** EF5
- **OTHER:** flow cytometry
- **OTHER:** immunohistochemistry staining method

## Key facts

- **NCT ID:** NCT00041028
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2007-09
- **Final completion:** 2014-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041028, "EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00041028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*